Gastrointestinal Cancer News

The M2-PK Quick, a rapid point-of-care stool test that detects the oncoprotein M2 pyruvate kinase, provided a highly accurate diagnosis of colorectal cancer, according to recent study data.

The FDA granted orphan drug designation to melphalan for the treatment of patients with cholangiocarcinoma, according to a press release from Delcath Systems.

Women with intrahepatic cholestasis of pregnancy had an increased risk for developing hepatobiliary cancer and immune-mediated and cardiovascular diseases over time compared with women who did not, according to study data.

The Singapore Liver Cancer Recurrence Score was accurate in predicting outcomes for Singaporean patients who underwent resection for hepatocellular carcinoma, according to published findings.

Preoperative endoscopic ultrasound-guided fine needle aspiration was not associated with worse survival in patients with resected pancreatic cancer and instead pointed to “improved outcomes,” according to recent study data.

The use of immunotherapy in cancer, often called immuno-oncology, involves the stimulation of a person’s immune system to target and attack cancer cells.

Patients with colorectal cancer diagnosed during screening colonoscopy survived longer than those whose cancer was confirmed during diagnostic colonoscopy, according to recent study data.

Various body composition components, including sarcopenia, intramuscular fat deposition and visceral adiposity, were accurate in predicting mortality and other outcomes in patients with hepatocellular carcinoma, according to study findings.

The addition of cetuximab to FOLFOX chemotherapy prolonged PFS in patients with metastatic colorectal cancer who had progressed following first-line treatment and who did not harbor KRAS, NRAS, BRAF or PIK3CA mutations, according to study results presented at the European Society for Medical Oncology’s World Congress on Gastrointestinal Cancer.

Blueprint Medicines announced that the FDA has approved two Investigational New Drug applications to begin phase 1 clinical trials for BLU-554 for the treatment of advanced hepatocellular carcinoma and cholangiocarcinoma, and BLU-285 for gastrointestinal stromal tumor, according to a press release from the manufacturer.